Full Press Release Details
REGENERON RECEIVES FAST-TRACK DESIGNATION FOR THE IL-1 TRAP IN CIAS 1-ASSOCIATED PERIODIC SYNDROMES (CAPS) Data from Pivotal Trial Expected in Second Half of 2006.
REGN
REGENERON RECEIVES FAST-TRACK DESIGNATION FOR THE IL-1 TRAP IN CIAS 1-ASSOCIATED PERIODIC SYNDROMES (CAPS) Data from Pivotal Trial Expected in Second Half of 2006
Key Takeaway: REGENERON RECEIVES FAST-TRACK DESIGNATION FOR THE IL-1 TRAP IN CIAS 1-ASSOCIATED PERIODIC SYNDROMES (CAPS) Data from Pivotal Trial Expected in Second Half of 2006
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema